key: cord-0970732-hg62xkri authors: Liu, Anna; Raja xavier, Janet; Singh, Yogesh; Brucker, Sara Y.; Salker, Madhuri S. title: Molecular and Physiological Aspects of SARS-CoV-2 Infection in Women and Pregnancy date: 2022-02-24 journal: Front Glob Womens Health DOI: 10.3389/fgwh.2022.756362 sha: c823d8645e20eb862027e40723972023907223b9 doc_id: 970732 cord_uid: hg62xkri Whilst scientific knowledge about SARS-CoV-2 and COVID-19 is rapidly increasing, much of the effects on pregnant women is still unknown. To accommodate pregnancy, the human endometrium must undergo a physiological transformation called decidualization. These changes encompass the remodeling of endometrial immune cells leading to immunotolerance of the semi-allogenic conceptus as well as defense against pathogens. The angiotensin converting enzyme 2 (ACE2) plays an important regulatory role in the renin-angiotensin-system (RAS) and has been shown to be protective against comorbidities known to worsen COVID-19 outcomes. Furthermore, ACE2 is also crucial for decidualization and thus for early gestation. An astounding gender difference has been found in COVID-19 with male patients presenting with more severe cases and higher mortality rates. This could be attributed to differences in sex chromosomes, hormone levels and behavior patterns. Despite profound changes in the female body during pregnancy, expectant mothers do not face worse outcomes compared with non-pregnant women. Whereas mother-to-child transmission through respiratory droplets during labor or in the postnatal period is known, another question of in utero transmission remains unanswered. Evidence of placental SARS-CoV-2 infection and expression of viral entry receptors at the maternal-fetal interface suggests the possibility of in utero transmission. SARS-CoV-2 can cause further harm through placental damage, maternal systemic inflammation, and hindered access to health care during the pandemic. More research on the effects of COVID-19 during early pregnancy as well as vaccination and treatment options for gravid patients is urgently needed. Since its emergence in December 2019 in Wuhan, China, the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has infected over 250 million people and caused more than 4.9 million deaths worldwide (as of October 2021) (1, 2) . The disease caused by SARS-CoV-2 is termed Coronavirus Disease 2019 (COVID- 19) and was declared a global pandemic in March 2020 (3) . Whilst scientific knowledge about this disease is rapidly increasing, much of its effects on pregnant women is still unknown. Pregnancy is a unique physiological state during which the female body undergoes profound transformations. The immune system is altered during pregnancy, resulting in immunotolerance of the semi-allogenic conceptus as well as protection of both mother and fetus against pathogens (4) . Research indicates that during pregnancy, expectant mothers are more susceptible to some infectious diseases, such as influenza or Ebola (5, 6) . The aim of this review is to illustrate what is known about COVID-19 and how it affects pregnancy. First, changes in the human endometrium enabling embryo implantation and pregnancy will be discussed -a process coined decidualization. Special emphasis will be put on the endometrial immune microenvironment, angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2). What follows is a brief overview of SARS-CoV-2 and of COVID-19. The review will further describe the gender differences found in COVID-19 and offer possible explanations. Lastly, what is known about implications of COVID-19 infection during pregnancy will be reviewed, with particular focus on the possibility of vertical transmission of SARS-CoV-2. The human menstrual cycle is approximately 28 days long and can be divided into two phases: the follicular (proliferative) phase and the luteal (secretory) phase (7, 8) . The start of each cycle is marked by the onset of menstruation (9) . During the first phase, estrogen is produced by granulosa cells in the ovaries, which leads to thickening of the endometrium (7) . This thickening is the result of proliferating epithelial and stromal cells, as well as angiogenesis (7, 10) . Ovulation marks the start of the second phase, when the corpus luteum produces progesterone, further preparing the endometrium for the possibility of embryo implantation and pregnancy; a process known as decidualization (11, 12) . In the case of no pregnancy, the corpus luteum deteriorates leading to a drop in progesterone levels, vasoconstriction in the endometrium with hypoxia and desquamation of the stratum functionalis (11) (12) (13) . The process of decidualization involves the differentiation of endometrial stromal cells, which are of mesenchymal origin and resemble fibroblasts, into decidual cells, similar to epithelial cells (Figure 1 ) (14) (15) (16) . During this mesenchymal-epithelial transition, the cells become larger and rounder with an expansion of the rough endoplasmic reticulum and the Golgi apparatus (11, 14) . There is an increase in the number of nucleoli and an accumulation of lipid and glycogen droplets within the cytoplasm (11, 16) . It was also shown that polyploidy is common among decidual cells, which might limit their lifespan but could benefit the growth of the embryo due to increased protein synthesis (17, 18). Decidual cells produce large quantities of prolactin and insulin-like growth factor binding protein-1, among others, which can also be used as bona fide markers for decidualization (11, 14) . The human endometrium is subject to cyclic transformations to provide an optimal environment for embryo implantation, however, the window of implantation is brief (19) . The uterus is only receptive to a blastocyst during the limited duration of about 4 days, approximately 6 to 10 days after ovulation (20, 21) . Not only does decidualization influence the timing of implantation but it also controls the extent of invasion by the embryo (22). Some studies even suggest that decidual cells are not passively invaded by the trophoblast but actively encapsulate the embryo (23-25). Moreover, the endometrium has the capability to sense the quality of the conceptus and makes a distinction between healthy and impaired embryos (26, 27) . Therefore, the decidua promotes implantation of high-quality embryos while rejecting developmentally impaired ones through modulation of gene expression (26-28). Defective decidualization can lead to a plethora of pregnancy complications such as preeclampsia, preterm birth or even recurrent pregnancy loss, highlighting the importance of adequate decidualization in early pregnancy (15, 29). Changes in morphology and function are not solely limited to stromal cells. Remodeling of the extracellular matrix as well as cell-cell interactions play a crucial role in decidualization (30, 31). Since pregnancy requires a well-calibrated balance between immunological responsiveness and tolerance, immune cells are another relevant component of the decidua (32, 33). During early pregnancy, up to 40% of all cells within the decidual tissue are leukocytes, such as macrophages, T and B cells and, most prominently, uterine natural killer cells (uNK) (34). The latter sees an increase in number during decidualization and is most abundant in the vicinity of spiral arteries, endometrial glands and at the maternal-fetal interface (7, 35) . Although their function is not completely clear, studies suggest that uNK are involved in remodeling of spiral arteries, clearance of senescent decidual cells, regulating maternal immune tolerance and defense against pathogens (15, 35, 36) . The maternal immune system is modulated during pregnancy, which is particularly meaningful when trying to understand the effects of COVID-19 on pregnancy and vice versa. The decidualized cells play an important role in providing immunotolerance toward the allogenic embryo by modulating the spectrum of immune cells at the maternal-fetal interface (32, 37). While there are plenty uNK cells (70% of total leukocytes) and macrophages (20-25%) in the decidual tissue, dendritic cells and B and T lymphocytes are rare (11, 32, 38) . It has been shown that dendritic cells, which regularly trigger T cell reaction, are entrapped in the tissue through decidualization and that their density throughout the decidua is reduced (39) . Due to this entrapment, the dendritic cells are ineffective in facilitating T cell activation, thus, lowering the chance of immunological attack on the fetus. Furthermore, decidual cells inhibit T cell proliferation, suppress inflammation and prompt apoptosis of activated T cells via the expression of Galectin-1, indoleamine-2,3-dioxygenase and FAS-ligand (40) (41) (42) . In summary, decidualization is part of the cyclic morphological alterations in the endometrium. This process is of utmost importance for embryo implantation and early pregnancy. Decidualization mainly encompasses modifications FIGURE 1 | Menstrual cycle and decidualization. The human menstrual cycle repeats itself in 28-day intervals. The start is marked by the onset of menstruation. Subsequently, the endometrium enters the proliferative phase, during which it increases in thickness as a response to high estrogen levels (pink, dotted line). In the secretory phase, decidualization occurs with remodeling of spiral arteries, mesenchymal-epithelial transition of stromal cells and alterations in the endometrial immune system, e.g., increase in uterine natural killer cells. These changes are triggered and regulated by progesterone (green, dashed line) and mainly take place in the upper part of the endometrium, the stratum functionalis, which is also shed during menstruation. ACE2 expression is increased by decidualization in the secretory phase (red, solid line). in endometrial stromal cells and is regulated predominantly by progesterone. Further, changes also occur in endometrial immune cells, and uNK cells are of particular interest, as they play an important role in endometrial remodeling during decidualization as well as immune tolerance and defense. The angiotensin-converting enzyme 2 (ACE2) is a typical zinc metallopeptidase that plays an important role in the reninangiotensin system (RAS) (43) . It is an integral membrane glycoprotein, consisting of 805 amino acids and containing a single catalytic domain (44) . Major functions of ACE2 include converting angiotensin (Ang) I into Ang 1-9 and Ang II into Ang 1-7 (45, 46) . ACE typically converts Ang I into Ang II, causing vasoconstriction, leading to inflammation and fibrosis, ACE2 can be seen as a counterbalance to ACE (44) . Thus, ACE2 is a negative regulator of RAS and therefore crucial in regulating blood pressure, fluid and electrolyte balance (Figure 2 ) (47) . Despite being expressed ubiquitously in the human body, some tissues contain remarkably high amounts of ACE2 including the kidneys, heart, lungs, testes and intestines as well as endothelial and vascular smooth muscle cells (43, 48, 49) . ACE2expressing tissues are potential targets for SARS-CoV-2 (50) . Notably, ACE2 has been shown to be protective against heart failure, hypertension, diabetes, renal dysfunction and pulmonary diseases (51) (52) (53) (54) (55) . These are also comorbidities that have been identified to worsen the outcome of COVID-19 patients, which might be linked to a dysregulation of RAS (43, 56, 57) . After facilitating the entry of SARS-CoV-2 into the host cell, ACE2 FIGURE 2 | The renin-angiotensin-system and ACE2. Triggered by low blood pressure, low blood volume and low sodium levels as well as sympathetic activity, the kidney secretes renin. Renin, a protease, cleaves angiotensinogen, secreted by the liver, into angiotensin I. Angiotensin I is then converted by the angiotensin-converting enzyme, which can be found in membranes of endothelial cells most abundantly in the lungs and kidneys, into angiotensin II. Various effects are caused by angiotensin II, which ultimately result in an increase of blood pressure and volume. The angiotensin-converting enzyme 2 works as a counterbalance to ACE by cleaving angiotensin I and angiotensin II into Ang 1-9* and Ang 1-7, respectively. (*Ang1-9 is postulated to exert similar effects as Ang1-7, though current data is limited and needs further validation). Activation of this pathway leads to vasodilation, inhibits cell proliferation and has anti-inflammatory effects. During pregnancy, maternal and fetal tissues contribute to the production of ACE2, leading to systemic vasodilation. expression is downregulated (58) . Loss of ACE2 is initiated during virus infection since the SARS-CoV-2-ACE2-complex is internalized through endocytosis (59, 60) . This depletion of ACE2 leads to a dysregulation of RAS, further aggravating harmful effects of COVID-19, such as acute respiratory distress syndrome (ARDS) and endothelial dysfunction (61) (62) (63) . A controversial debate over the continued usage of angiotensin II receptor blockers and ACE inhibitors among COVID-19 patients with preexisting hypertension arose after the ACE2 receptor became known as the entry factor for SARS-CoV-2 (64). Since these drugs were thought to increase the expression of ACE2, it was hypothesized that their application would lead to higher infection rates and more severe COVID-19 cases (65, 66) . However, several studies found no significant difference between patients treated with or without ACE inhibitors and/or angiotensin II receptor blockers regarding the infection rate and COVID-19 outcome (67) (68) (69) (70) . Controversially, others even reported a lowered risk of SARS-CoV-2 infection or critical illness and death, respectively (71, 72) . Notably, it was speculated that geographic and ethnic factors may influence the interaction between these drugs and COVID-19 (69, 71) . Further studies are required to substantiate these findings. The influence of gender and age on ACE2 expression is not fully understood yet. While several studies did not prove significant differences of ACE2 expression between young males and females (<55 years), it has been shown that the correlation between ACE2 and immune signatures in the lungs differ between the two sexes (49, (73) (74) (75) . There have been contrasting results regarding the relation of ACE2 content to increasing age, with some finding an increase, a decrease, or no change at all (49, 73, 74) . However, it has been suggested that steroid hormones may affect ACE2 activity with withdrawal of estrogen or testosterone causing an increase or a decrease, respectively (75) . Another important albeit overlooked function of ACE2 was illustrated in a recent study. Chadchan et al. found that the ACE2 protein is not only highly expressed in human endometrial stromal cells (HESCs), in particular during the secretory phase of the menstrual cycle, but it also increases significantly in stromal cells undergoing decidualization in vitro (76) . They further observed that loss of ACE2 impeded decidualization (76) . Additionally, Chadchan et al. described that ACE2 expression in the endometrium is induced by progesterone. Considering these results, it is plausible that ACE2 plays a vital role in decidualization of the human endometrium. Furthermore, other studies have found that ACE2 and other components of RAS are expressed both in maternal and fetal tissues during pregnancy, suggesting their crucial role during implantation, vascular remodeling and labor (77) (78) (79) (80) (81) . During pregnancy, the uterus and placenta contribute substantially to ACE2 production, thus causing a twofold increase in ACE2 activity with subsequent systemic vasodilation (82) . The upregulation of RAS in the maternal decidua as well as in the endothelial and perivascular stromal cells during the first trimester of pregnancy coincides with spiral artery remodeling and angiogenesis (83) . Dysregulation of uteroplacental RAS is reported to alter the tightly regulated maternal homeostasis causing pregnancy complications such as miscarriage, still birth and preeclampsia (84) (85) (86) . It was also shown that plasma Ang 1-7, a product of ACE2, is elevated during healthy pregnancies and that preeclamptic mothers had lower levels of Ang 1-7 (87) . Remarkably, ACE2 is most abundant in the decidua in comparison with chorionic or amniotic tissues (77) . Another compelling finding is that ACE2 expression is highest during early pregnancy and is negatively correlated with gestational age (88, 89) . Moreover, fetal sex might affect maternal RAS and for instance, ACE2 mRNA levels were higher in decidual explants after 24h from women carrying a female fetus compared with those carrying a male fetus (90) . Briefly, ACE2 has essential functions for the RAS and contributes to the control of blood pressure as well as fluid and electrolyte homeostasis. ACE2 is expressed in various tissues throughout the human body and is protective against cardiovascular and respiratory diseases, among others. ACE2 is essential for decidualization and its production increases during pregnancy. Since ACE2 is also the entry receptor for SARS-CoV-2, its high expression in placental tissues has implications for pregnancies during COVID-19 infection, which will be covered in detail below. SARS-CoV-2 belongs to the same genus betacoronavirus as SARS-CoV and MERS-CoV, which are all enveloped viruses with a single-stranded positive-sense RNA (91, 92) . Although the origin of SARS-CoV-2 has not been fully clarified yet, it is most likely that it originated from bats, which are a natural reservoir for coronaviruses, and was passed on to humans via an intermediate host such as pangolins (93, 94) . SARS-CoV-2 consists of four structural proteins: spike (S), nucleocapsid (N), membrane (M) and envelope (E) protein (95) . The S-protein is of utmost interest, as it facilitates virus entry into host cells (96, 97) . Due to the similarity of their S-proteins, SARS-CoV and SARS-CoV-2 both utilize the cell surface receptor ACE2 for attachment and penetration of host cells (97) . However, the receptor-binding domain (RBD) of the S-protein differs among SARS-CoV and SARS-CoV-2, resulting in higher binding affinity to ACE2 of the latter (98) . A precondition for the interaction of SARS-CoV-2 with ACE2 is S-protein priming by host proteases, among which the most relevant seems to be transmembrane protease serine 2 (TMPRSS2) (Figure 3 ) (99) . The main route of transmission is through respiratory droplets, nevertheless, SARS-CoV-2 can be further spread via aerosols, direct and indirect contact, and feces (100) (101) (102) (103) . While it has been suggested that SARS-CoV-2 could be passed on via sexual contact and breastfeeding, more evidence is necessary (104, 105) . For COVID-19, the incubation period, defined as the time between infection and onset of symptoms, is approximately 5 days (106, 107) . The basic reproduction number R 0 of SARS-CoV-2 is estimated to lie between 2 and 3 with a peak viral load in the upper respiratory tract around symptom onset or shortly after (108) (109) (110) . Not only can patients be infectious 1 to 3 days before any symptoms occur, but there have also been reports of asymptomatic transmission (110, 111) . The clinical presentation of COVID-19 varies greatly from asymptomatic and mild to critical and even fatal cases (112) . Diagnosis is further impeded by unspecific symptoms, which resemble the clinical picture of the common cold, influenza or other respiratory diseases (113) . The most common manifestations are fever and cough, which are present in the majority of the patients, followed by fatigue and shortness of breath (50, 92, 114) . Anosmia, ageusia, myalgia and diarrhea are less frequent among COVID-19 patients (115, 116) . Some symptoms, for instance fatigue or dyspnea, can persist despite microbiological recovery -a condition termed Long COVID (117, 118) . COVID-19 originally revealed itself through an outbreak of pneumonia (97) . In severe cases, patients develop ARDS with hypoxia or even respiratory failure (119) . Histopathological findings are diffuse alveolar damage with desquamation of pneumocytes, formation of hyaline membranes, edema and inflammatory infiltration by lymphocytes, as well as microvascular injury (120, 121) . Correspondingly, chest computed tomography (CT) scans of COVID-19 patients commonly show bilateral distribution of ground-glass opacities with or without consolidations, "crazy paving" patterns and air bronchogram signs (122, 123) . COVID-19 not only involves the lungs and the respiratory tract, but also multiple organ systems (124) . This includes cardiovascular (e.g. acute cardiac injury, myocarditis), gastrointestinal (e.g. nausea and vomiting, diarrhea), neurological (e.g. dizziness, stroke) and hematological manifestations (e.g. lymphocytopenia, thrombotic events, disseminated intravascular coagulation (DIC)) (124) (125) (126) (127) (128) . A case point feature of COVID-19 is, that it triggers an extensive inflammatory response, the "cytokine storm", which further aggravates damage done by the virus (129) . A delay in immune response due to immune evasion of SARS-CoV-2 with consequentially unhindered virus replication is found in severe cases of COVID-19 (130) (131) (132) . Virus-induced cell death prompts the recruitment of macrophages and neutrophils, followed by hyperinflammation (130) . Subsequent tissue damage and multi-organ failure are the main cause of death in COVID-19 (133, 134) . The vast majority (80-90%) of COVID-19 cases are asymptomatic or mildly symptomatic, whereas among the critically ill the mortality rate is as high as 49% (112, 119, 135) . The most important prognostic factor is age, with children mainly being asymptomatic or only exhibiting mild symptoms whereas elderly patients are at high risk for mortality (136) (137) (138) . Other factors contributing to poor outcome are comorbidities such as hypertension, heart disease, diabetes mellitus, Chronic Obstructive Pulmonary Disease (COPD) and chronic renal disease (139) (140) (141) . Furthermore, obesity and the male sex have been linked to increased severity of COVID-19 (141) (142) (143) . Genetic factors also have an impact on COVID-19 infection and outcome with some studies suggesting links to HLA or ABO blood type ( Historically, women were overlooked in biomedical research and the male model was seen as the "norm". Women were and are still underrepresented in clinical trials due to the notion that studies could be complicated by the menstrual cycle and that a potential fetus could be harmed (173) . This practice of exclusion from clinical trials is even more common for pregnant women (174) . Indeed, sex discrepancy also applies to animal models with a male bias in the majority of research fields (175). The belief that male data can be simply extrapolated to women leads to inadequate treatment of female patients, such as wrong dosage of drugs or more severe side effects (173, 176) . An astounding gender difference has been found in COVID-19; in that whilst infection rates are similar in both sexes, men are prone to having more severe infection and higher mortality (two-to threefold) (138, 144, 145, 177) . Likewise, this bias toward males was also present in the MERS outbreak in 2014 (178) . However, this pattern was not as consistent in the previous SARS epidemic in 2002, with only one study showing a significant difference in case fatality ratio between men and women (179, 180) . Controversially, another review even reported that mainly females were affected by SARS (181) . One possible rationale for the female advantage lies in the sex chromosomes (182, 183) . Since women possess two X-chromosomes, one of the X-chromosomes is silenced to compensate gene dosage (184) . Some genes escape inactivation resulting in differential expression between sexes (185) . The gene of the SARS-CoV-2 receptor ACE2 is located on the Xchromosome and is further recognized as an escape gene (185, 186) . This implies that women might be in a more favorable position of elevated ACE2 expression which counterbalances the downregulation of ACE2 upon SARS-CoV-2 infection and therefore protects from an overactive RAS. However, expression does not equal enzyme activity and as described above, sex differential expression of ACE2 is still controversial (187, 188) . Notably, soluble ACE2 (sACE2), which is generated through shedding of membrane-bound ACE2, was found to be higher in men compared with women as well as postmenopausal compared with premenopausal women (189) (190) (191) . As higher levels of sACE2 are correlated with cardiovascular disease and diabetes, known risk factors for more severe cases of COVID-19, this may contribute to the male disadvantage (192) . Another potential link between genetics and the purported reduced risk in females is the fact that the X-chromosome contains a great repertoire of immune-related genes (193) . It is noteworthy that women generally mount a faster and stronger innate and adaptive immune response whereas men are subject to reduced immune response and higher pathogen load (194) . X-linked genes are suggested to play a pivotal role in autoimmune diseases, which are characterized by a heightened immune response against the patient's own cells and primarily affect women (195, 196) . Genes encoding for pattern recognition Association with COVID-19 Age Children and younger people generally exhibit more asymptomatic or mild cases, whereas older patients are at higher risk for severe cases and death (136) (137) (138) . The male sex is associated with higher infection rates and worse outcomes compared with the female sex (138, (143) (144) (145) . Socioeconomic status People with lower income are at increased risk of COVID-19 infection and higher mortality compared to those with higher income (146, 147) . Most common comorbidity among COVID-19 patients, increases risk for poor outcome (138) (139) (140) 143) Heart disease Increases risk for poor outcome (138) (139) (140) (141) 143) Diabetes mellitus Type 1 and type 2 diabetes as well as uncontrolled hyperglycemia increase the risk for poor COVID-19 outcome (139, 140, 143, (148) (149) (150) . The association between high HbA 1c and increased mortality remains controversial (151) (152) (153) (154) . Especially for type 2 diabetes, use of insulin is linked to higher mortality (153, 155) . Increases risk for poor outcome (139, 140, 143, 156) Chronic kidney disease Increases risk for poor outcome (141, 157) Obesity Increases risk for poor outcome (140) (141) (142) (143) Cancer Increases risk for poor outcome (139, 141, 158) Chronic liver disease Increases risk for poor outcome (159, 160) Genetic factors ACE2 (Angiotensin-converting enzyme 2) Some polymorphisms increase susceptibility to SARS-CoV-2 (e.g., S19P, K26R, E23K), others hinder interactions between the spike protein and ACE2 (e.g., K31R, N33I, E329G) (161, 162) . TMPRSS2 (Transmembrane serine protease 2) Some variants are linked to increased TMPRSS2 expression and higher susceptibility to SARS-CoV-2 (e.g., rs12329760) (163) . Variants encoding proteins with low binding affinity to SARS-CoV-2 (e.g., B*46:01, C*14:02) increase vulnerability, whereas variants encoding proteins with high binding affinity to SARS-CoV-2 (e.g., B*15:03, A*02:02) encourage immunity (164, 165) . Increases risk for poor outcome (156, 168) Alcohol abuse Uncertain, likely increases risk for poor outcome (169, 170) Physical activity Decreases risk for poor outcome (171, 172) * indicates Nomenclature of HLA alleles. receptors (PRRs) have a vital function in the innate immune system and consequently are of special interest regarding the delayed immune response in COVID-19 (197) . Among them, Toll-like receptor 7 (TLR7) is not only responsible for the recognition of single-stranded viral RNA in endosomes, but its gene is also located on the X-chromosome and known to escape silencing in immune cells (198) (199) (200) . Furthermore, reaction to TLR7 stimulation also differs depending on sex as peripheral blood mononuclear cells from females produce more Interferon-α (IFN-α), eliciting an anti-viral response, whereas in males higher production of Interleukin-10 (IL-10), an immunosuppressive cytokine, is induced (201, 202) . Considering that differences in the immune response between the sexes occurs across all age groups, it is perhaps plausible that sex chromosomes are part of the reason why females seem to clear pathogens faster and have less severe COVID-19 cases (203) . Endocrine factors are another conceivable explanation for sex disparities in COVID-19 outcomes as the mortality rate in postmenopausal women is higher than in premenopausal women (204, 205) . Estrogen has potent immunomodulatory effects and estrogen receptors are expressed by several immune cells (206) . At high concentrations, as found periovulatory or during pregnancy, estrogen has mainly anti-inflammatory effects, for instance decreasing levels of C-reactive protein (CRP), IL-6 and TNF-α (207) (208) (209) (210) . In contrast, estrogen triggers pro-inflammatory pathways at lower doses (211) . Furthermore, estrogen has proven to reduce morbidity of influenza infection through modifying immune cell recruitment and cytokine production, as well as scaling down virus replication in females (212, 213) . Despite less elderly women succumbing to COVID-19 in comparison to elderly men, climacteric women are still at higher risk of worse outcomes than their premenopausal counterparts, and futher, estradiol treatment was shown to improve survival (214, 215) . Certain comorbidities are known to negatively impact COVID-19 outcomes; it is noteworthy that the prevalence of hypertension, diabetes and COPD is lower in the female population (216) (217) (218) . This can be attributed to women leading healthier lifestyles, such as less smoking, lower alcohol consumption and more physical activity (219) (220) (221) . Nonetheless, biological factors might also have an impact on the development of the said comorbidities. Aside from ACE2 activity positively correlating with estrogen levels, protective effects of estrogen on atrial tissue through modulation of RAS and upregulation of ACE2 were observed (222, 223) . Moreover, in a study on mice, obese females had higher adipose ACE2 activity and, unlike obese males, did not develop hypertension (224) . When ovariectomized, female mice also showed reduced ACE2 activity and obesity-hypertension, which could be reversed through treatment with estrogen (224, 225) . Akin to estrogen's shielding properties in hypertension, estrogen also guards premenopausal women from diabetes mellitus and estrogen replacement therapy in postmenopausal patients is beneficial for metabolic health (226, 227) . In respect to COVID-19, it is noteworthy to point out that estrogen was shown to decrease ACE2 expression of differentiated airway epithelial cells, providing another clue for sex-difference in infection (228) . In summary, COVID-19 affects men with disproportionately higher infection rates, more severe cases, and higher mortality than women. This can be attributed to sex chromosomes, as the ACE2 gene lies on the X-chromosome and is known to escape silencing. Several genes related to immune response are also located on the X-chromosome, resulting in a faster and stronger immune defense in females. Additionally, hormones might cause sex differences in COVID-19 outcomes. High concentrations of estrogen have anti-inflammatory properties, thereby alleviating the detrimental effects of the cytokine storm in COVID-19. Lastly, women tend to have less comorbidities than men, due to healthier lifestyles and the protective effects of estrogen. Pregnancy is a unique physiological condition with changes in the endocrine system (e.g., high levels of cortisol, progesterone and estrogen), cardiovascular system (e.g., increased cardiac output, decreased systemic vascular resistance, higher blood volume) and respiratory system (e.g., swelling of upper respiratory tract, elevated diaphragm, lower total lung capacity, hyperventilation) (229, 230) . Considering COVID-19, physiologically elevated basal oxygen consumption levels, a predisposition to developing lung edema and dyspnea, as well as hypercoagulability are all relevant during pregnancy (231-234). According to a meta-analysis from Di Toro et al. which included 1,100 pregnancies, most pregnant women infected with SARS-CoV-2 had uncomplicated clinical courses with frequent symptoms being fever and cough, pneumonia was prevalent in 89% of the cases (235) . They further found an ICU admission rate of 8% and 5 maternal deaths, implying that pregnant women do not face worse outcomes than non-pregnant women. Other studies have also found pregnant COVID-19 patients to have similar clinical characteristics and disease outcomes as nonpregnant women (236, 237) . Conversely, higher admission rates to ICU and a higher risk for more severe COVID-19 cases was reported among pregnant compared with non-pregnant patients (238) (239) (240) . Advanced maternal age, comorbidities such as diabetes mellitus, hypertension, low socioeconomic status as well as obesity have all been identified as possible risk factors for maternal death from COVID-19 (241) . The current pandemic has resulted in the requirement to transform and adapt healthcare services for pregnant women in high-risk groups including women with gestational diabetes mellitus (GDM) or diabetes mellitus. GDM is the most common medical complication of pregnancy and affects 10% of pregnancies globally. Those diagnosed with this condition are at higher risk for a severe COVID-19 infection due to predisposing factors such as hyperglycemia, obesity and hypertension (242) . Critically, the most common underlying conditions of pregnant women with SARS-CoV-2 that were hospitalized for severe disease were pre-pregnancy BMI ≥30 kg/m 2 (41.7%) and diabetes mellitus (Type 2) (12.5%) (243) . An interplay of several pathophysiological mechanisms is thought to increase the risk of an unfavorable course and a worse prognosis for patients with GDM. In general, diabetes or insulin resistance reduces T cell function leading to an impaired immune response. This results in the global cellular dysfunction underlying a variety of symptoms associated with diabetes, including a higher risk of respiratory infections (244) . Moreover, it has been indicated that some COVID-19 patients develop a diabeteslike syndrome (245) . Taken together, these factors could lead to poor pregnancy outcomes including pre-term labor, neonatal admissions to ICU or still birth. Therefore, several healthcare guidelines from the NIH (USA), STIKO/Robert Koch Institute (Germany) and the RCOG (UK) have emphatically expressed the urgency for pregnant women (diabetic and/or obese) to be vaccinated. Commonly reported neonatal complications are preterm birth, premature rupture of membranes and fetal distress, while intrauterine growth restriction, miscarriage and death are rare events (246, 247) . The high cesarean section rate (85%) among COVID-19 positive women is noteworthy, despite COVID-19 not posing a contraindication for vaginal delivery (235) . Possibly, improved infection control during labor explains the preference for C-section, however, vaginal fluids were repeatedly tested were negative for SARS-CoV-2, indicating low risk for intrapartum transmission (246, 247) . Vertical transmission describes the process of ante-, perior postnatal mother-to-child transmission of infectious agents (248) . The focus of this review will be on vertical transmission before birth, meaning in utero infection of the fetus. Several bacteria, viruses and parasites are known to cause congenital infection, the most common one being the cytomegalovirus (CMV) (249) . The consequences of these infections depend on the pathogens, with some causing fetal death (e.g., parvovirus B19, mumps virus, rubella virus) and others leading to malformations or organ defects (e.g., Chlamydia trachomatis, Treponema pallidum, CMV, Toxoplasma gondii) (250) . Another determinant of teratogenicity is the time of infection: the rubella virus causes cerebral, cardiac, ophthalmic and auditory defects when infection occurs in the first trimester of pregnancy (during organogenesis), whereas the fetus is most vulnerable to the hemolytic effect of parvovirus B19 and subsequent hydrops fetalis during the second trimester, due to heightened hematopoiesis in the fetal liver (Figure 4) (250, 251) . While SARS-CoV-2 can be passed from mother to infant through respiratory droplets during labor or in the postnatal period, the question of in utero transmission remains unresolved (252) . Infection rates among neonates born to COVID-19 positive mothers are low (6%), however, cases of early-onset COVID-19 exist with infants testing positive via nasopharyngeal swabs within 12 h postpartum (235, 253) . Further, antibodies against SARS-CoV-2 identified in newborns shed additional light on the possibility of prenatal vertical transmission (254, 255) . In contrast to IgG, which is subject to physiological transplacental transfer and therefore could originate from maternal blood, elevated levels of IgM indicate infection of the fetus in utero, as IgM usually does not cross the placental barrier (256) . Nevertheless, inflammatory processes can affect the placental barrier and result in altered transfer of immunoglobulin (257) . Thus, elevated IgM levels in neonates are no definite proof for in utero transmission of SARS-CoV-2. Furthermore, in a study from Hecht et al. SARS-CoV-2 RNA was detected in the syncytiotrophoblast and cytotrophoblast of placentas from COVID-19 positive mothers (258) . This demonstrates that SARS-CoV-2 can infect the placenta, however, it does not definitely confirm vertical transmission. Further, these women were tested (positive for COVID-19) peripartum, limiting the insights into late pregnancy infection. A potential way for vertical transmission of SARS-CoV-2 during pregnancy is via ACE2. As reviewed above, ACE2 is expressed in fetal and maternal tissues during pregnancy and most amply so in the early stages (77-81, 88, 89) . Strong coexpression of ACE2 and TMPRSS2, necessary for cleavage of the spike protein, at the maternal-fetal-interface was reported by some studies (78, 259) . In contrast, when examining expression patterns of ACE2 and TMPRSS2 in placentas, Pique-Regi et al. only found negligible co-transcription, especially compared to receptors for Zika virus and CMV, both known to cause congenital infections (260) . While ACE2 was repeatedly shown to be present in endometrial and placental tissues, research on TMPRSS2 is inconclusive (258, 260, 261) . It should be noted that low expression of TMPRSS2 does not necessarily equal low risk of SARS-CoV-2 infection. Other proteases have been suggested to provide an alternate pathway for viral cell entry, such as TMPRSS4, furin or cathepsin L (94) . Notably, TMPRSS4 is expressed alongside ACE2 in the endometrium and, akin to ACE2, increases toward the window of implantation (261) . Furthermore, TMPRSS4 has the capacity of facilitating cell entry of SARS-CoV-2, thus, making it a candidate for promoting vertical transmission (262) . Another option for in utero transmission of SARS-CoV-2 while omitting ACE2 is through infected blood cells. While viremia in COVID-19 exists, only low levels of SARS-CoV-2 RNA are detectable in blood of infected patients (263, 264) . When studying the full-term placenta from a COVID-19 positive mother whose newborn was also tested positive, Facchetti et al. showed that viral proteins and RNA were present in numerous fetal and maternal cells (265) . Of particular interest is the finding that fetal monocytes were infected with SARS-CoV-2, thus, providing a potential vehicle for vertical transmission. When interpreting results regarding vertical transmission, it must be considered that most studies solely include mothers tested positive for COVID-19 during the third trimester or peripartum and little attention has been devoted to early pregnancy. Recently, Valdespino-Vázquez et al. examined placental and fetal tissues from a miscarriage during the first trimester of a COVID-19 positive patient (266) . They found viral proteins and RNA as well as hyper-inflammation present in both the placenta and the fetal organs (266) . As organogenesis occurs in early pregnancy, infection during this crucial time would have detrimental effects on the fetal outcome. Additionally, a case report on a first trimester COVID-19 infection indicated, not only that SARS-CoV-2 persists in the placenta, but it also infected the amniotic fluid and fetal membranes (267) . Strikingly, while the mother remained asymptomatic, her unborn succumbed to hydrops fetalis and death (267) . Therefore, more research on COVID-19 and its effects on early pregnancy is urgently needed. Indeed, vertical transmission is not the only way a pathogen can harm an unborn infant. Firstly, SARS-CoV-2 is known to cause placental damage, including maternal and fetal vascular malperfusion, decidual arteriopathy, intervillous thrombi as well as inflammation (e.g., villitis, intervillositis, chorioamnitis) (268) (269) (270) . Abnormal ACE2 expression caused by SARS-CoV-2 infection in both decidua and placenta could potentially impair key physiological processes, such as placentation and vascularization during pregnancy (271) . Hence, dysregulation of RAS could play a critical role in developing preeclampsia-like placental pathology, COVID-19 associated miscarriages and still births. Placental impairment leads to compromised fetal supply of oxygen and nutrients with subsequent complications, such as intrauterine growth restriction or miscarriage, independent of vertical transmission (272) . Remarkably, placental pathology exists even in mild or asymptomatic cases of COVID-19 (273, 274) . Aside from locally impacting the placenta, COVID-19 is a systemic disease and the maternal immune response can result in fetal injury (250) . Being subjected to an inflammatory milieu, can damage the lungs and brain of the developing fetus (250) . Likewise, maternal fever and upper respiratory infection, both characteristics of COVID-19, are linked to congenital heart disease (275) . Deleterious effects of the cytokine storm induced by SARS-CoV-2 are not confined to the pregnant woman but could also affect the fetus, possibly resulting in multi-organ failure and ultimately fetal demise (276) . Of equal importance are psychological implications of the ongoing pandemic, such as higher rates of depression and anxiety among pregnant women, which might impact health and well-being of both mother and child (277, 278) . Psychological stress is a known risk factor for miscarriage, especially during early pregnancy, which might be linked to elevated cortisol levels (279, 280) . Furthermore, the pandemic lead to hampered access to pre-and postnatal care services, possibly contributing to underdiagnosis of complications (281) . Interestingly, pregnant women were found to be at lower risk for depressive symptoms in comparison to non-pregnant women and mothers delivering during the COVID-19 pandemic had reduced risk of postpartum-depression than before the pandemic (282, 283) . This points to substantial psychological resilience among expectant mothers. In general, gravid patients present certain challenges to medical treatment. As mentioned above, pregnant women exhibit edema and swelling in the upper respiratory tract, thereby complicating endotracheal intubation (229) . Moreover, pregnancy has implications on medication used to treat COVID-19 and vice versa; for example, Favipiravir, an antiviral drug used against COVID-19, should not be administered during pregnancy, and for magnesium sulfate, used for prophylaxis and treatment of preeclampsia, dosage adjustment is required in COVID-19 patients (284, 285) . While vaccination is seen as a promising way to resolve the COVID-19 pandemic, pregnant women were not included in clinical trials and, accordingly, a lack of evidence exists regarding safety and efficacy of COVID-19 vaccines in pregnancy (286) . This not only resulted in differing recommendations from national and international organizations regarding vaccination against SARS-CoV-2 during pregnancy, but also in confusion and low acceptance among pregnant women (287, 288) . Very recently, evidence about the safety and effectiveness of COVID-19 vaccines for pregnant women is emerging. Preliminary data indicates that vaccination against COVID-19 during pregnancy and lactation is safe regarding maternal side effects, female fertility as well as pregnancy and neonatal outcomes (289, 290) . Based on 35,691 volunteers during or shortly before pregnancy, participants did not report any adverse side effects among pregnant women who received mRNA COVID-19 vaccines either from Pfizer/BioNTech or Moderna (290) . It was demonstrated for COVID-19 mRNA vaccines that not only an immune response could be elicited in pregnant and lactating women but also that the antibodies could be passed onto their infants through the umbilical cord blood and breast milk (291) (292) (293) (294) . Given the ongoing pandemic, further research is urgently needed to provide reliable recommendations for the vaccination of pregnant and lactating women. This review describes the impact of COVID-19 on non-pregnant and pregnant women. Its aim is to explore why the SARS-CoV-2 infection affects men more severely than women and bringing knowledge about genetic, endocrine and exogenous factors together. Different ways of how COVID-19 can harm pregnant mothers and neonates are discussed and currently available data on the possibility of vertical transmission is summarized. This review intends to connect the pathophysiology of COVID-19 to the physiology of pregnancy, decidualization and RAS. While knowledge on COVID-19 is increasing rapidly, a lack of evidence for the impact on pregnancy remains. Although the currently available data shows that non-pregnant and pregnant women seem to be less affected in terms of severity and mortality, little is known about the long-term effects of viral infection on the fetus. Vertical transmission seems to be rare, but neither is the possibility of in utero transmission excluded, nor are the effects of the maternal immune response on the unborn fully understood. Considering the therapeutic obstacles that the pandemic poses on pregnant COVID-19 patients, further research is needed to improve maternal and fetal management. Notably, a major part of research on COVID-19 and pregnancy focuses explicitly on the third trimester, resulting in a lack of knowledge concerning adverse effects and vertical transmission during early pregnancy. With new SARS-CoV-2 variants emerging, continuous effort is required to shed light on their consequences for pregnancy as well as lactation. Furthermore, pregnant women should not be excluded in future clinical trials for COVID-19 vaccines and therapies. Scientific progress will enable doctors and health workers to provide evidence-based treatments for pregnant women. AL, MS, and JR performed information retrieval and/or analyzed data. MS, YS, and SB provided intellectual input, resources, and funding. AL wrote the original draft of the manuscript and drew the figures. The presented work here is used in MD thesis of AL. All authors reviewed the manuscript and approved of submission. A. novel coronavirus outbreak of global health concern Available online at int/director-general/speeches/detail/who-director-general-s-openingremarks-at-the-media-briefing-on-covid The immune system in pregnancy: a unique complexity The impact of influenza virus infection in pregnancy Viral infections during pregnancy Physiologic events of embryo implantation and decidualization in human and non-human primates Physiology of the Endometrium and Regulation of Menstruation A role for menstruation in preconditioning the uterus for successful pregnancy Reproductive ecology and the endometrium: physiology, variation, and new directions Cyclic decidualization of the human endometrium in reproductive health and failure Evaluating the influence of progesterone concentration and time of exposure on in vitro endometrial decidualisation Ultrastructure of the microvasculature in the human endometrium throughout the normal menstrual cycle Decidualization of the human endometrium: mechanisms, functions, and clinical perspectives Clearance of senescent decidual cells by uterine natural killer cells in cycling human endometrium Alternative theories: Pregnancy and immune tolerance Endometrial immune dysfunction in recurrent pregnancy loss Dendritic cell entrapment within the pregnant uterus inhibits immune surveillance of the maternal/fetal interface in mice Galectin-1 influences trophoblast immune evasion and emerges as a predictive factor for the outcome of pregnancy The role of indoleamine-2,3-dioxygenase in normal and pathological pregnancies An insight into the role of the death receptor CD95 throughout pregnancy: guardian, facilitator, or foe Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2 The emerging role of ACE2 in physiology and disease A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9 Angiotensin converting enzyme 2: a double-edged sword Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review Role of the ACE2/Angiotensin 1-7 axis of the renin-angiotensin system in heart failure Angiotensin-converting enzyme 2 is an essential regulator of heart function The sweeter side of ACE2: physiological evidence for a role in diabetes Loss of ACE2 accelerates time-dependent glomerular and tubulointerstitial damage in streptozotocin-induced diabetic mice Angiotensinconverting enzyme 2 protects from severe acute lung failure COVID-19 and comorbidities: deleterious impact on infected patients Organ-protective effect of angiotensinconverting enzyme 2 and its effect on the prognosis of COVID-19 The pivotal link between ACE2 deficiency and SARS-CoV-2 infection SARS coronavirus entry into host cells through a novel clathrin-and caveolae-independent endocytic pathway Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV Disequilibrium between the classic renin-angiotensin system and its opposing arm in SARS-CoV-2-related lung injury COVID-19, Renin-Angiotensin System and Endothelial Dysfunction COVID-19 and RAS: unravelling an unclear relationship Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Risks of ACE inhibitor and ARB usage in COVID-19: evaluating the evidence Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: a meta-analysis Renin-angiotensin system inhibitors and COVID-19: a systematic review and meta-analysis. Evidence for significant geographical disparities Renin-angiotensin-aldosterone system inhibitors and risk of Covid-19 Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 83 million people Effects of angiotensin II receptor blockers and ACE (angiotensinconverting enzyme) inhibitors on virus infection, inflammatory status, and clinical outcomes in patients with COVID-19 and hypertension: a single-center retrospective study Sex differences in the aging pattern of renin-angiotensin system serum peptidases Age-and gender-related difference of ACE2 expression in rat lung Sex hormones promote opposite effects on ACE and ACE2 activity, hypertrophy and cardiac contractility in spontaneously hypertensive rats The SARS-CoV-2 receptor, angiotensin-converting enzyme 2, is required for human endometrial stromal cell decidualization † Molecular characterization of renin-angiotensin system components in human intrauterine tissues and fetal membranes from vaginal delivery and cesarean section Expression of SARS-CoV-2 receptor ACE2 and the protease TMPRSS2 suggests susceptibility of the human embryo in the first trimester Distribution of angiotensin-(1-7) and ACE2 in human placentas of normal and pathological pregnancies Utero-placental expression of angiotensin-(1-7) and ACE2 in the pregnant guinea-pig The SARS-CoV-2 receptor ACE2 expression of maternal-fetal interface and fetal organs by single-cell transcriptome study ACE2 expression and activity are enhanced during pregnancy Human spiral artery renin-angiotensin system Renin angiotensin signaling in normal pregnancy and preeclampsia The functional role of the renin-angiotensin system in pregnancy and preeclampsia The renin-angiotensin-aldosterone system in pre-eclampsia: the delicate balance between good and bad Angiotensin-(1-7) in normal and preeclamptic pregnancy Expression of severe acute respiratory syndrome coronavirus 2 cell entry genes, angiotensin-converting enzyme 2 and transmembrane protease serine 2, in the placenta across gestation and at the maternal-fetal interface in pregnancies complicated by preterm birth or preeclampsia -7) in the rat uterus during early and late gestation Fetal sex affects expression of renin-angiotensin system components in term human decidua Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding pathogenesis, diagnosis and in-line treatment of COVID Genomic Perspective on the Origin and Emergence of SARS-CoV-2 Characteristics of SARS-CoV-2 and COVID-19 SARS-CoV-2: structure, biology, and structure-based therapeutics development Angiotensinconverting enzyme 2 is a functional receptor for the SARS coronavirus A pneumonia outbreak associated with a new coronavirus of probable bat origin Structural basis of receptor recognition by SARS-CoV-2 SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor The airborne lifetime of small speech droplets and their potential importance in SARS-CoV-2 transmission Aerosol transmission of SARS-CoV-2? Evidence, prevention and control SARS-CoV-2 transmission channels: a review of the literature The presence of SARS-CoV-2 RNA in the feces of COVID-19 patients Clinical characteristics and results of semen tests among men with coronavirus disease 2019 Detection of SARS-CoV-2 in human breastmilk The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application Incubation period of COVID-19: a rapid systematic review and meta-analysis of observational research Epidemiology of SARS-CoV-2 Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19 SARS-CoV-2 detection, viral load and infectivity over the course of an infection SARS-CoV-2: the viral shedding vs infectivity dilemma COVID-19 pandemic-a focused review for clinicians COVID-19: Progress in diagnostics, therapy and vaccination Clinical characteristics of coronavirus disease 2019 in China SARS-CoV-2 and the pandemic of COVID-19 Alterations in smell or taste in mildly symptomatic outpatients with SARS-CoV-2 infection Persistent symptoms in patients after acute COVID-19 Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: a cross-sectional evaluation Severe COVID-19 Pathological findings of COVID-19 associated with acute respiratory distress syndrome Pulmonary pathology and COVID-19: lessons from autopsy. The experience of European Pulmonary Pathologists Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review CT manifestations and clinical characteristics of 1115 patients with coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis Extra-respiratory manifestations of COVID-19 Cardiovascular Manifestations of COVID-19 Infection Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis Challenges and management of neurological and psychiatric manifestations in SARS-CoV-2 (COVID-19) patients Hematologic disorders associated with COVID-19: a review The COVID-19 cytokine storm; what we know so far COVID-19: Immunology and treatment options Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection Immune responses during COVID-19 infection Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) Outbreak in China: summary of a report of 72 314 cases from the chinese center for disease control and prevention The COVID-19 pandemic: a global health crisis Clinical characteristics of COVID-19 in children: a systematic review Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Clinical characteristics of 82 cases of death from COVID-19 Dying with SARS-CoV-2 infection-an autopsy study of the first consecutive Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study Obesity and its impact on COVID-19 Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area Gender differences in patients with COVID-19: focus on severity and mortality Impact of sex and gender on COVID-19 outcomes in Europe Disparities in the population at risk of severe illness from COVID-19 by race/ethnicity and income Association of social and demographic factors with COVID-19 incidence and death rates in the US Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes Preadmission diabetes-specific risk factors for mortality in hospitalized patients with diabetes and coronavirus disease 2019 Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study Insulin treatment is associated with increased mortality in patients with COVID-19 and type 2 diabetes The impact of COPD and smoking history on the severity of COVID-19: a systemic review and meta-analysis Chronic kidney disease and acute kidney injury in the COVID-19 Spanish outbreak COVID-19 in cancer patients: risk, clinical features, and management Prevalence of chronic liver disease in patients with COVID-19 and their clinical outcomes: a systematic review and meta-analysis Clinical characteristics and outcomes of coronavirus disease 2019 among patients with preexisting liver disease in the United States: a multicenter research network study Human ACE2 receptor polymorphisms predict SARS-CoV-2 susceptibility. bioRxiv Structural variations in human ACE2 may influence its binding with SARS-CoV-2 spike protein ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy Human leukocyte antigen susceptibility map for severe acute respiratory syndrome coronavirus 2 Initial wholegenome sequencing and analysis of the host genetic contribution to COVID-19 severity and susceptibility Relationship between the ABO Blood Group and the COVID-19 Susceptibility Dinse-Lambracht A. Association between the dynamics of the COVID-19 epidemic and ABO blood type distribution Smoking is associated with COVID-19 progression: a meta-analysis Network meta-analysis on the mechanisms underlying alcohol augmentation of COVID-19 pathologies Alcohol use disorder: a pre-existing condition for COVID-19? Lifestyle risk factors, inflammatory mechanisms, and COVID-19 hospitalization: A communitybased cohort study of 387,109 adults in UK Physical exercise as a tool to help the immune system against COVID-19: an integrative review of the current literature Women's health and clinical trials Beery AK, Zucker I. Sex bias in neuroscience and biomedical research Gender differences in atrial fibrillation: a review of epidemiology, management, and outcomes Disparities in age-specific morbidity and mortality from SARS-CoV-2 in China and the Republic of Korea The pattern of Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive epidemiological analysis of data from the Saudi Ministry of Health Case fatality of SARS in mainland China and associated risk factors Do men have a higher case fatality rate of severe acute respiratory syndrome than women do? Sex differences in COVID-19: candidate pathways, genetics of ACE2, and sex hormones The X chromosome and sex-specific effects in infectious disease susceptibility X-chromosome inactivation and escape Landscape of X chromosome inactivation across human tissues human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase Sex-specific changes in renal angiotensin-converting enzyme and angiotensin-converting enzyme 2 gene expression and enzyme activity at birth and over the first year of life Discrepancy between intrarenal messenger RNA and protein expression of ACE and ACE2 in human diabetic nephropathy Age and sex differences in soluble ACE2 may give insights for COVID-19 Circulating plasma concentrations of angiotensinconverting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors Plasma levels of soluble ACE2are associated with sex, Metabolic Syndrome, and its biomarkers in a large cohort, pointing to a possible mechanism for increased severity in COVID-19 Potential detrimental role of soluble ACE2 in severe COVID-19 comorbid patients The X chromosome in immune functions: when a chromosome makes the difference Sex differences in immune responses Female predominance and X chromosome defects in autoimmune diseases Sex bias in autoimmunity Pathogen recognition and innate immunity Innate antiviral responses by means of TLR7-mediated recognition of single-stranded TLR7 escapes X chromosome inactivation in immune cells Sexual dimorphism in innate immunity TLR7 ligands induce higher IFN-alpha production in females Sex differences in the response to viral infections: TLR8 and TLR9 ligand stimulation induce higher IL10 production in males Sex-based differences in immune function and responses to vaccination COVID-19 outcomes in postmenopausal and perimenopausal females: is estrogen hormone attributing to gender differences? Potential influence of menstrual status and sex hormones on female SARS-CoV-2 infection: a cross-sectional study from multicentre in Wuhan, China Sex differences in severity and mortality from COVID-19: are males more vulnerable? Estrogen and related compounds: biphasic dose responses Endogenous reproductive hormones and Creactive protein across the menstrual cycle: the BioCycle study Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappa B and C/EBP beta Estrogen decreases TNF-alpha and oxidized LDL induced apoptosis in endothelial cells The complex role of estrogens in inflammation 17β-estradiol protects females against influenza by recruiting neutrophils and increasing virus-specific CD8 T cell responses in the lungs Estrogenic compounds reduce influenza A virus replication in primary human nasal epithelial cells derived from female, but not male, donors The severe acute respiratory syndrome due to coronavirus 2 (SARS-CoV-2) infection and the climacteric woman Evidence for treatment with estradiol for women with SARS-CoV-2 infection Hypertension prevalence, awareness, treatment and control in Germany 1998 and 2008-11 Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus Gender-specific estimates of COPD prevalence: a systematic review and meta-analysis Erol A, Karpyak VM. Sex and gender-related differences in alcohol use and its consequences: contemporary knowledge and future research considerations age and socioeconomic variation in 24-hour physical activity by wrist-worn accelerometers: the FinHealth Association of angiotensin-converting enzyme 2 gene polymorphism and enzymatic activity with essential hypertension in different gender: a case-control study Protective regulation of the ACE2/ACE gene expression by estrogen in human atrial tissue from elderly men Angiotensin converting enzyme 2 contributes to sex differences in the development of obesity hypertension in C57BL/6 mice Administration of 17β-estradiol to ovariectomized obese female mice reverses obesity-hypertension through an ACE2-dependent mechanism Role of estrogen in type 1 and type 2 diabetes mellitus: a review of clinical and preclinical data Combined estrogen replacement therapy on metabolic control in postmenopausal women with diabetes mellitus Estrogen regulates the expression of SARS-CoV-2 receptor ACE2 in differentiated airway epithelial cells Alterations in physiology and anatomy during pregnancy Physiological changes during pregnancy Pulmonary edema in pregnancy Coagulation in pregnancy Impact of COVID-19 on maternal and neonatal outcomes: a systematic review and meta-analysis Coronavirus disease 2019 (COVID-19) and pregnancy: a systematic review Coronavirus disease 2019 infection among asymptomatic and symptomatic pregnant women: two weeks of confirmed presentations to an affiliated pair of New York City hospitals Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis Public Health Agency of Sweden's Brief Report: Pregnant and postpartum women with severe acute respiratory syndrome coronavirus 2 infection in intensive care in Sweden Clinical characteristics of 46 pregnant women with a severe acute respiratory syndrome coronavirus 2 infection in Washington State Comorbidities, poverty and social vulnerability as risk factors for mortality in pregnant women with confirmed SARS-CoV-2 infection: analysis of 13 062 positive pregnancies including 176 maternal deaths in Mexico SARS-CoV-2 in diabetic pregnancies: a systematic scoping review COVID-19 vaccination in pregnant and lactating diabetic women Why is COVID-19 more severe in patients with diabetes? The role of angiotensin-converting enzyme 2, endothelial dysfunction and the immunoinflammatory system COVID-19 and diabetes mellitus: from pathophysiology to clinical management Clinical characteristics and outcomes of pregnant women with COVID-19 and the risk of vertical transmission: a systematic review COVID-19 infection in pregnant women: Review of maternal and fetal outcomes Microbial vertical transmission during human pregnancy Diagnosis and antenatal management of congenital cytomegalovirus infection Influence of infection during pregnancy on fetal development Parvovirus B19 infection in human pregnancy Vertical transmission of coronavirus disease 19 (COVID-19) from infected pregnant mothers to neonates: a review COVID-19 in pregnant women: a systematic review and meta-analysis Antibodies in infants born to mothers with COVID-19 pneumonia Possible vertical transmission of SARS-CoV-2 from an infected mother to her newborn IgG placental transfer in healthy and pathological pregnancies Transport of maternal immunoglobulins through the human placental barrier in normal pregnancy and during inflammation SARS-CoV-2 can infect the placenta and is not associated with specific placental histopathology: a series of 19 placentas from COVID-19-positive mothers SARS-CoV-2 Entry Factors: ACE2 and TMPRSS2 Are Expressed in Peri-Implantation Embryos and the Maternal-Fetal Interface. Engineering (Beijing) Does the human placenta express the canonical cell entry mediators for SARS-CoV-2? Elife SARS-CoV-2 infection risk assessment in the endometrium: viral infection-related gene expression across the menstrual cycle TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes Evidence and possible mechanisms of rare maternal-fetal transmission of SARS-CoV Detection of SARS-CoV-2 in different types of clinical specimens SARS-CoV2 vertical transmission with adverse effects on the newborn revealed through integrated immunohistochemical, electron microscopy and molecular analyses of Fetal and placental infection with SARS-CoV-2 in early pregnancy Persistence of SARS-CoV-2 in the first trimester placenta leading to transplacental transmission and fetal demise from an asymptomatic mother SARS-CoV-2 and placenta: new insights and perspectives Placental pathology in COVID-19 A structured review of placental morphology and histopathological lesions associated with SARS-CoV-2 infection Role of ACE2 in pregnancy and potential implications for COVID-19 susceptibility Human placenta and trophoblast development: key molecular mechanisms and model systems Placental SARS-CoV-2 in a pregnant woman with mild COVID-19 disease COVID-19 as an independent risk factor for subclinical placental dysfunction Associations of maternal upper respiratory tract infection/influenza during early pregnancy with congenital heart disease in offspring: evidence from a case-control study and meta-analysis COVID-19 and Pregnancy: Vertical Transmission and Inflammation Impact on Newborns Elevated depression and anxiety symptoms among pregnant individuals during the COVID-19 pandemic Perinatal depressive and anxiety symptoms of pregnant women during the coronavirus disease 2019 outbreak in China Recurrent miscarriage: current concepts in diagnosis and treatment Cortisol levels and very early pregnancy loss in humans Pandemics and maternal health: the indirect effects of COVID-19 Women's depressive symptoms during the COVID-19 pandemic: the role of pregnancy Risk for probable post-partum depression among women during the COVID-19 pandemic Pregnancy and COVID-19: pharmacologic considerations Antiviral agent therapy optimization in special populations of COVID-19 patients Coronavirus disease 2019 (COVID-19) vaccines and pregnancy: what obstetricians need to know Alignment of national COVID-19 vaccine recommendations for pregnant and lactating women Intention to receive COVID-19 vaccine during pregnancy: a systematic review and meta-analysis COVID-19 vaccination in pregnancy and lactation: current research and gaps in understanding Preliminary findings of mRNA Covid-19 vaccine safety in pregnant persons Immunogenicity of COVID-19 mRNA vaccines in pregnant and lactating women Efficient maternal to neonatal transfer of antibodies against SARS-CoV-2 and BNT162b2 mRNA COVID-19 vaccine Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study SARS-CoV-2 vaccine effectiveness in preventing confirmed infection in pregnant women All figures were created with BioRender.com. Figure 2 was adapted from Renin-Angiotensin System by BioRender.com. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.Copyright © 2022 Liu, Raja xavier, Singh, Brucker and Salker. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.